SEARCH

SEARCH BY CITATION

References

  • 1
    Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000;36:600603.
  • 2
    Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1997;278:17451748.
  • 3
    Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829837.
  • 4
    Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med. 2002;162:23252332.
  • 5
    Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:11871192.
  • 6
    Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:12951297.
  • 7
    Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:13261331.
  • 8
    Byington RP, Craven TE, Furberg CD, et al. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet. 1997;350:10751076.
  • 9
    Wagenknecht LE, Furberg CD, Hammon JW, et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995;310:776777.
  • 10
    Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:10611065.
  • 11
    Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493497.
  • 12
    Wang TJ, Ausiello JC, Stafford RS. Trends in anti-hypertensive drug advertising, 1985–1996. Circulation. 1999;99:20552057.
  • 13
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA. 2002;288:29812997.
  • 14
    Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341:14471457.
  • 15
    Morel N, Buryi V, Feron O, et al. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998;125:10051012.
  • 16
    Soldatov NM, Bouron A, Reuter H. Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants. J Biol Chem. 1995;270:1054010543.
  • 17
    Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol. 1995;75:4549.
  • 18
    McNamara RL, Tamariz LJ, Segal JB, et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003;139:10181033.
  • 19
    Leenen FH, Ruzicka M, Huang BS. Central sympathoinhibitory effects of calcium channel blockers. Curr Hypertens Rep. 2001;3:314321.
  • 20
    Krusell LR, Christensen CK, Lederballe Pedersen O. Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls–a proximal tubular effect? Eur J Clin Pharmacol. 1987;32:121126.
  • 21
    Terzoli L, Leonetti G, Pedretti R, et al. Nifedipine does not blunt the aldosterone and cardiovascular response to angiotensin II and potassium infusion in hypertensive patients. J Cardiovasc Pharmacol. 1988;11:317320.
  • 22
    Yang Z, Noll G, Luscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993;88:832836.
  • 23
    van Zwieten PA, van Meel JC, Timmermans PB. Pharmacology of calcium entry blockers: interaction with vascular alpha-adrenoceptors. Hypertension. 1983;5:II8II17.
  • 24
    Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. State of the art. Am J Med. 1989;86:2732.
  • 25
    Nayler WG. Vascular injury: mechanisms and manifestations. Am J Med. 1991;90:8S13S.
  • 26
    Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 1996;276:785791.
  • 27
    Zanchetti A, Rosei EA, Dal Palu C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16:16671676.
  • 28
    Griffin KA, Picken MM, Bakris GL, et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:18491860.
  • 29
    Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:12831289.
  • 30
    Pedrinelli R, Salvetti A. Heterogeneous interference of nicardipine, verapamil, and diltiazem with forearm arteriolar responsiveness to adrenergic stimulation in hypertensive patients. Am Heart J. 1991;122:342351.
  • 31
    Elliott WJ, Prisant LM. Controlled-release formulations of calcium antagonist. In: EpsteinM, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, PA: Hanley & Belfus Inc; 2002:139150.
  • 32
    Herbette LG, Vecchiarelli M, Sartani A, et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl. 1998;2:1017.
  • 33
    Neutel JM, Alderman M, Anders RJ, et al. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J. 1996;132:12021206.
  • 34
    White WB, Anders RJ, MacIntyre JM, et al. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group. Am J Cardiol. 1995;76:375380.
  • 35
    Prisant LM, Devane JG, Butler J. A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours. Am J Ther. 2000;7:345351.
  • 36
    Sista S, Lai JC, Eradiri O, et al. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration. J Clin Pharmacol. 2003;43:11491157.
  • 37
    McAllister RG Jr, Schloemer GL, Hamann SR. Kinetics and dynamics of calcium entry antagonists in systemic hypertension. Am J Cardiol. 1986;57:16D21D.
  • 38
    Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1991;41:478505.
  • 39
    Sica DA, Gehr TWB. Calcium channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens. 2003;12:123131.
  • 40
    McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989;38:1976.
  • 41
    Prisant LM. Calcium antagonists. In: Hypertension: A Companion to Brenner and Rector's The Kidney. OparilS, WeberM, eds. 2nd ed. Philadelphia, PA: WB Saunders; 2005:683704.
  • 42
    Weir MR, Zachariah P. Verapamil. In: MesserliF, ed. Cardiovascular Drug Therapy. 2nd ed. Philadelphia, PA: WB Saunders; 1996;915930.
  • 43
    Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219230.
  • 44
    Prisant LM, Elliott WJ. Drug delivery systems for treatment of systemic hypertension. Clin Pharmacokinet. 2003;42:931940.
  • 45
    Swanson DR, Barclay BL, Wong PS, et al. Nifedipine gastrointestinal therapeutic system. Am J Med. 1987;83:389.
  • 46
    Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine (isradipine-CR). J Clin Pharmacol. 1995;35:239243.
  • 47
    Chung M, Reitberg DP, Gaffney M, et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am J Med. 1987;83:1014.
  • 48
    Prisant LM, Spaulding VC. Antihypertensive pharmacobezoar. J Clin Hypertens (Greenwich). 2006;8:296298.
  • 49
    Webster J, Petrie JC, Jeffers TA, et al. Nicardipine sustained release in hypertension. Br J Clin Pharmacol. 1991;32:433439.
  • 50
    Smith DH, Neutel JM, Weber MA. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens. 2001;14:1419.
  • 51
    Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens. 2006;19:768773.
  • 52
    Bailey DG, Arnold JM, Bend JR, et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol. 1995;40:135140.
  • 53
    Zaidenstein R, Dishi V, Gips M, et al. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol. 1998;54:337340.
  • 54
    Sigusch H, Henschel L, Kraul H, et al. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie. 1994;49:675679.
  • 55
    Frishman W, Opie L, Sica DA. Adverse cardiovascular drug interactions and complications. In: Hurst's The Heart. AlexanderRW, O'RourkeRA, eds. 11th ed. New York, NY: McGraw-Hill; 2004:21692188.
  • 56
    Sokol SI, Cheng-Lai A, Frishman WH, et al. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol. 2000;40:1130.
  • 57
    Hamann SR, Kaltenborn KE, Vore M, et al. Cardiovascular pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs. Am J Cardiol. 1985;56:147156.
  • 58
    Johnston DL, Gebhardt VA, Donald A, et al. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, cross-over study with radionuclide ventriculography. Circulation. 1983;68:12801289.
  • 59
    McInnes GT, Findlay IN, Murray G, et al. Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens Suppl. 1985;3:S219S221.
  • 60
    Pedersen KE. Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. Acta Med Scand Suppl. 1985;697:140.
  • 61
    Elliott HL, Meredith PA, Campbell L, et al. The combination of prazosin and verapamil in the treatment of essential hypertension. Clin Pharmacol Ther. 1988;43:554560.
  • 62
    Maisel AS, Motulsky HJ, Insel PA. Hypotension after quinidine plus verapamil: possible additive competition at alpha-adrenergic receptors. N Engl J Med. 1985;312:167171.
  • 63
    Trohman RG, Estes DM, Castellanos A, et al. Increased quinidine plasma concentrations during administration of verapamil: a new quinidine-verapamil interaction. Am J Cardiol. 1986;57:706707.
  • 64
    Messerli FH, Grossman E. Pedal edema—not all dihydropyridine calcium antagonists are created equal. Am J Hypertens. 2002;15:10191020.
  • 65
    Sica DA. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens (Greenwich). 2003;5:291294, 297.
  • 66
    Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15:932940.
  • 67
    Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:11821187.
  • 68
    Prisant LM, Herman W. Calcium channel blocker induced gingival overgrowth. J Clin Hypertens (Greenwich). 2002;4:310311.
  • 69
    Steele RM, Schuna AA, Schreiber RT. Calcium antagonist induced gingival hyperplasia. Ann Intern Med. 1994;120:663664.
  • 70
    Seymour RA, Ellis JS, Thomason JM. Drug-induced gingival overgrowth and its management. J R Coll Surg Edinb. 1993;38:328332.
  • 71
    Petersen KU, Jaspersen D. Medication-induced oesophageal disorders. Expert Opin Drug Saf. 2003;2:495507.
  • 72
    Felicetta JV, Serfer HM, Cutler NR, et al. A dose-response trial of once-daily diltiazem. Am Heart J. 1992;123:10221026.
  • 73
    Cutler NR, Anders RJ, Jhee SS, et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol. 1995;75:11021106.
  • 74
    White WB, Johnson MF, Anders RJ, et al. Safety of controlled onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. Am Heart J. 2001;142:10101015.
  • 75
    Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med. 2001;161:23372342.
  • 76
    Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:19541961.
  • 77
    Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38:273290.
  • 78
    Opie LH. Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. Prog Cardiovasc Dis. 1996;38:291314.
  • 79
    Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990;66:779785.
  • 80
    Scheidt S, Frishman WH, Packer M, et al. Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo controlled double-blind randomized clinical trials. Am J Cardiol. 1982;50:11851190.
  • 81
    Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996;17:7681.
  • 82
    Snow V, Barry P, Fihn SD, et al, for the American College of Physicians; American College of Cardiology Chronic Stable Angina Panel. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians [published correction appears in Ann Intern Med. 2005;142:79]. Ann Intern Med. 2004;141:562567.
  • 83
    Prisant LM. Verapamil revisited: a transition in novel drug delivery systems and outcomes. Heart Dis. 2001;3:5562.
  • 84
    Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol. 1999;83:507514.
  • 85
    Frishman W, Sica DA. Calcium channel blockers. In: Cardiovascular Pharmacotherapeutics. FrishmanW, SonnenblickS, SicaDA, eds. 2nd ed. New York, NY: McGraw-Hill; 2003:105130.
  • 86
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 87
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 88
    Cummings DM, Amadio P Jr, Nelson L, et al. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med. 1991;151:250259.
  • 89
    Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich). 2006;8:5356.
  • 90
    Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713724.
  • 91
    Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs Single-Drug Therapy of Hypertension Study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189192.
  • 92
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:28052816.
  • 93
    Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:20732082.
  • 94
    Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:17071713.
  • 95
    Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther. 2000;68:130142.
  • 96
    Steffen HM. Use of calcium channel antagonists for the treatment of hypertension in the elderly. Drugs Aging. 2004;21:565581.
  • 97
    White WB, Johnson MF, Black HR, et al. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. Am J Hypertens. 2001;14:12391247.
  • 98
    Gradman AH. Treatment of hypertension with felodipine in patients with concomitant diseases. Clin Cardiol. 1993;16:294301.
  • 99
    Chew CY, Hecht HS, Collett JT, et al. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol. 1981;47:917922.
  • 100
    Agodoa LY, Appel L, Bakris G, et al, for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:27192728.
  • 101
    Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005;46:637642.
  • 102
    Sica DA. Combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens (Greenwich). 2001;3:322327.
  • 103
    Lessem JN, Barone EJ, Berl T, et al. Nicardipine and propranolol in the treatment of essential hypertension. Am J Hypertens. 1989;2:146153.
  • 104
    Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens. 2000;13:921926.
  • 105
    Lenz ML, Pool JL, Laddu AR, et al. Combined tera-zosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995;8:133145.
  • 106
    Burris JF, Weir MR, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 1990;263:15071512.
  • 107
    Sica DA. Current concepts of pharmacotherapy in hypertension: thiazide-type diuretics: ongoing considerations on mechanism of action. J Clin Hypertens (Greenwich). 2004;6:661664.
  • 108
    Kaesemeyer WH, Carr AA, Bottini PB, et al. Verapamil and nifedipine in combination for the treatment of hypertension. J Clin Pharmacol. 1994;34:4851.
  • 109
    Sica DA. Novel combinations in the treatment of hypertension. Minerva Urol Nefrolo. 2005;57:129139.
  • 110
    Saseen JJ, Carter BL, Brown TE, et al. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28:109114.
  • 111
    Nicholson JP, Resnick LM, Laragh JH. The antihypertensive effect of verapamil at extremes of dietary sodium intake. Ann Intern Med. 1987;107:329334.
  • 112
    Chrysant SG, Weder AB, McCarron DA, et al. Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. Am J Hypertens. 2000;13:11801188.
  • 113
    Webster J. Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications. Drugs. 1985;30:3241.
  • 114
    Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991;90:42S47S.
  • 115
    Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107:628635.
  • 116
    Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781786.
  • 117
    Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med. 1995;155:10491054.
  • 118
    Klassen DK, Jane LH, Young DY, et al. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens. 1995;8:146153.
  • 119
    Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:11611167.
  • 120
    Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959963.
  • 121
    Mansoor GA, McCabe EJ, White WB. The long-term reproducibility of ambulatory blood pressure. J Hypertens. 1994;12:703708.
  • 122
    Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet. 1978;1:795797.
  • 123
    White WB. A chronotherapeutic approach to the management of hypertension. Am J Hypertens. 1996;9:29S33S.
  • 124
    Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol. 1999;83:507514.
  • 125
    Weber MA, Prisant LM, Black HR, et al. Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial. Am J Geriatr Cardiol. 2004;13:131136.
  • 126
    Dal Ponte DB, Fogt DL, Jacob S, et al. Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism. 1998;47:982987.
  • 127
    Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med. 2004;116:3543.
  • 128
    Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Reversal of cardiac hypertrophy by long-term treatment with calcium antagonists in hypertensive patients. J Cardiovasc Pharmacol. 1988;12(suppl 6):S75S78.
  • 129
    Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol. 1986;7:916924.
  • 130
    Smolensky MH, Portaluppi F. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease. Am Heart J. 1999;137:S14S24.
  • 131
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443462.
  • 132
    Zakopoulos NA, Tsivgoulis G, Barlas G, et al. Impact of the time rate of blood pressure variation on left ventricular mass. J Hypertens. 2006;24:20712077.
  • 133
    Kuriyama S, Otsuka Y, Iida R, et al. Morning blood pressure predicts hypertensive organ damage in patients with renal diseases: effect of intensive antihypertensive therapy in patients with diabetic nephropathy. Intern Med. 2005;44:12391246.
  • 134
    Kario K. Morning surge and variability in blood pressure: a new therapeutic target? Hypertension. 2005;45:485486.
  • 135
    Sica DA. Impact of antihypertensive therapy on the rate-pressure product: the role of chronotherapeutics. Eur Heart J. 1999;1(suppl B):B24B33.
  • 136
    Tutuian R, Castell DO. Review article: oesophageal spasm–diagnosis and management. Aliment Pharmacol Ther. 2006;23:13931402.
  • 137
    Loi CM, Rollins DE, Dukes GE, et al. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther. 1985;37:654657.
  • 138
    Smith MS, Benyunes MC, Bjornsson TD, et al. Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984;36:551554.
  • 139
    Stoepel K, Deck K, Corsing C, et al. Safety aspects of long-term nitrendipine therapy. J Cardiovasc Pharmacol. 1984;6:S1063S1066.
  • 140
    Williams G, Donaldson RM. Nifedipine and nocturia. Lancet. 1986;1:738.
  • 141
    Romero JC, Raij L, Granger JP, et al. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension. 1987;10:140151.
  • 142
    Watson NA, Fitzgerald CP. Management of massive verapamil overdose. Med J Aust. 1991;155:124125.
  • 143
    Hofer CA, Smith JK, Tenholder ME. Verapamil intoxication: a literature review of overdose and discussion of therapeutic options. Am J Med. 1993;95:431438.
  • 144
    Ashraf M, Chaudhary K, Nelson J, et al. Massive overdose of sustained-release verapamil: a case report and review of the literature. Am J Med Sci. 1995;310:258263.
  • 145
    ter Wee PM, Kremer Hovinga TK, Uges DR, et al. 4- Aminopyridine and haemodialysis in the treatment of verapamil intoxication. Hum Toxicol. 1985;4:327329.
  • 146
    Kuhlmann U, Schoenemann H, Muller TF, et al. Plasmapheresis in fatal overdose with verapamil. Intensive Care Med. 1999;25:1473.
  • 147
    Williamson KM, Dunham GD. Plasma concentrations of diltiazem and desacetyldiltiazem in an overdose situation. Ann Pharmacother. 1996;30:608611.
  • 148
    Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63:18281835.
  • 149
    Camargo PM, Melnick PR, Pirih FQ, et al. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2000. 2001;27:131138.
  • 150
    Fattore L, Stablein M, Bredfeldt G, et al. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dentist. 1991;11:107109.
  • 151
    Barclay S, Thomason JM, Idle JR, et al. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol. 1992;19:311314.
  • 152
    Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol. 1992;63:453456.
  • 153
    Tannergren C, Engman H, Knutson L, et al. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther. 2004;75:298309.
  • 154
    Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:10891096.
  • 155
    Inspra [prescribing information]. New York, NY: Pfizer Inc; 2003.
  • 156
    Yeo KR, Yeo WW, Wallis EJ, et al. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharmacol. 1999;48:610615.
  • 157
    Mousa O, Brater DC, Sundblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267274.
  • 158
    Picciotto G, Sargiotto A, Petrarulo M, et al. Reliability of captopril renography in patients under chronic therapy with angiotensin II (AT1) receptor antagonists. J Nucl Med. 2003;44:15741581.
  • 159
    Zuccala G, Onder G, Pedone C, et al. Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors. Eur J Clin Pharmacol. 2003;58:695699.
  • 160
    Lenz TL, Wurdeman RL, Hilleman DE. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. Pharmacotherapy. 2001;21:898903.
  • 161
    Wurdeman RL, Mooss AN, Mohiuddin SM, et al. Comparison of 24-hour ambulatory blood pressure data in hypertensive patients switched from nifedipine-GITS to nifedipine-CC. Pharmacotherapy. 1999;19:94100.
  • 162
    Ganz M, Mokabberi R, Sica DA. Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. J Clin Hypertens (Greenwich). 2005;7(suppl 1):2731.
  • 163
    Andresdottir MB, van Hamersvelt HW, van Helden MJ, et al. Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study. J Cardiovasc Pharmacol. 2000;35(3 suppl 1):S25S30.
  • 164
    Zanchetti A, Omboni S, La Commare P, et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001;38:642650.
  • 165
    Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients with lercanidipine or amlodipine. J Hypertens. 2003;21:10031010.
  • 166
    Glasser SP, Neutel JM, Gana TJ, et al. Efficacy and safety of once-daily graded-release diltiazem formulation in essential hypertension. Am J Hypertens. 2003;16:5158.
  • 167
    Pedrinelli R, Dell'Omo G, Melillo E, et al. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35:621625.
  • 168
    Pang CC. Autonomic control of the venous system in health and disease. Effects of drugs. Pharmacol Ther. 2001;90:179230.
  • 169
    Turnbull F, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:15271535.
  • 170
    Staessen JA, Wang JG, Thijs L, et al. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:13051315.
  • 171
    Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386392.